VEGFA and Abnormal retinal morphology: Antibody therapies do not require a viral vector system for delivery and are a commonly used treatment for neovascular retinal diseases, particularly anti-VEGF treatments, such as aflibercept, bevacizumab, and faricimab [10,43,224].